What happened with PLSM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pulsenmore Ltd.’s Pulsenmore ES lets pregnant patients scan at home, using a compact ultrasound device connected to a smartphone and an app. Patients can scan with app guidance or remote clinician guidance, then share images with healthcare providers for monitoring and consultation. Insurers, health maintenance organizations and hospitals buy the devices for distribution to patients; device sales, rather than support services, are the main source of product and service revenue.
That business is concentrated in Israel and depends heavily on Clalit Health Services, its main customer and distribution partner. Sheba Medical Center also distributes ES devices to prenatal patients. Pulsenmore FC, intended for home examinations during fertility treatment, is at an early commercialization stage in Israel.
Product and service revenue remains limited, and Pulsenmore has relied mainly on issuing shares to fund operations. Sales depend on healthcare providers accepting the devices and on maintaining regulatory authorization for each market and use. ES is approved or cleared in the United States and several other markets; FC is approved in Israel. Israeli research-grant rules also generally require prior approval to transfer grant-supported technology or related manufacturing abroad.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Pulsenmore’s recurring device sales hinge chiefly on Clalit Health Services’ purchases and adoption of home prenatal scanning, while its GE HealthCare settlement supplied most of its reported 2025 revenue.
GE HealthCare both sells competing VScan ultrasound devices to healthcare providers and has bought Pulsenmore devices for distribution, but the 2025 settlement canceled outstanding orders and ended future purchase obligations. That settlement contributed NIS 30.5 million of Pulsenmore’s NIS 40.0 million revenue in 2025, so fresh device orders—not settlement revenue—are what to watch for ongoing sales.
Butterfly Network, Inc. competes indirectly for clinicians evaluating Pulsenmore’s remote-imaging offering: it sells handheld ultrasound devices for trained medical staff, rather than a matching patient-operated home scanner. Watch developments in its IQ+ remote-diagnostics offering for competitive pressure on Pulsenmore ES, which Pulsenmore currently sells directly to insurers, HMO organizations and hospitals for home prenatal scanning.
GE HealthCare Technologies Inc. earningsGEHC
GE HealthCare's report will show whether the company that sells competing ultrasound devices and once bought Pulsenmore's home scanners has resumed buying, a signal of whether Pulsenmore can replace one-off settlement revenue with recurring device sales.
Look for fresh device orders from GE HealthCare, separate from Pulsenmore's ES sales through Clalit and Sheba. New orders would show that this channel is again generating device revenue and broaden Pulsenmore's sources of customers; no orders would confirm that the 2025 settlement was one-off revenue and ongoing sales still depend mainly on Clalit and Sheba.
